Characterization of Epithelial-Mesenchymal Transition Identifies a Gene Signature for Predicting Clinical Outcomes and Therapeutic Responses in Bladder Cancer

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2022 Dec 2

PMID 36457546

Authors

Yicun Wang

Hao Zhang

Xiaopeng Hu

Affiliations

Soon will be listed here.

Abstract

Purpose: The complex etiological variables and high heterogeneity of bladder cancer (BC) make prognostic prediction challenging. We aimed to develop a robust and promising gene signature using advanced machine learning methods for predicting the prognosis and therapy responses of BC patients.

Methods: The single-sample gene set enrichment analysis (ssGSEA) algorithm and univariable Cox regression were used to identify the primary risk hallmark among the various cancer hallmarks. Machine learning methods were then combined with survival and differential gene expression analyses to construct a novel prognostic signature, which would be validated in two additional independent cohorts. Moreover, relationships between this signature and therapy responses were also identified. Functional enrichment analysis and immune cell estimation were also conducted to provide insights into the potential mechanisms of BC.

Results: Epithelial-mesenchymal transition (EMT) was identified as the primary risk factor for the survival of BC patients (HR=1.43, 95% CI: 1.26-1.63). A novel EMT-related gene signature was constructed and validated in three independent cohorts, showing stable and accurate performance in predicting clinical outcomes. Furthermore, high-risk patients had poor prognoses and multivariable Cox regression analysis revealed this to be an independent risk factor for patient survival. CD8+ T cells, Tregs, and M2 macrophages were found abundantly in the tumor microenvironment of high-risk patients. Moreover, it was anticipated that high-risk patients would be more sensitive to chemotherapeutic drugs, while low-risk patients would benefit more from immunotherapy.

Conclusions: We successfully identified and validated a novel EMT-related gene signature for predicting clinical outcomes and therapy responses in BC patients, which may be useful in clinical practice for risk stratification and individualized treatment.

Citing Articles

Comprehensive characterization of endoplasmic reticulum stress in bladder cancer revealing the association with tumor immune microenvironment and prognosis.

Lin Y, Li T, Li Z, Shen C, Wu Z, Zhang Z Front Genet. 2023; 14:1097179.

PMID: 37091788 PMC: 10119429. DOI: 10.3389/fgene.2023.1097179.

References

Peinado H, Olmeda D, Cano A . Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer. 2007; 7(6):415-28. DOI: 10.1038/nrc2131. View

Shan G, Zhou X, Gu J, Zhou D, Cheng W, Wu H . Downregulated exosomal microRNA-148b-3p in cancer associated fibroblasts enhance chemosensitivity of bladder cancer cells by downregulating the Wnt/β-catenin pathway and upregulating PTEN. Cell Oncol (Dordr). 2021; 44(1):45-59. PMC: 7906940. DOI: 10.1007/s13402-020-00500-0. View

Sharma P, Shen Y, Wen S, Yamada S, Jungbluth A, Gnjatic S . CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A. 2007; 104(10):3967-72. PMC: 1820692. DOI: 10.1073/pnas.0611618104. View

Chen L, Gibbons D, Goswami S, Cortez M, Ahn Y, Byers L . Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014; 5:5241. PMC: 4212319. DOI: 10.1038/ncomms6241. View

Sayan A, Griffiths T, Pal R, Browne G, Ruddick A, Yagci T . SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. Proc Natl Acad Sci U S A. 2009; 106(35):14884-9. PMC: 2736415. DOI: 10.1073/pnas.0902042106. View

Sanchez-Carbayo M, Socci N, Lozano J, Saint F, Cordon-Cardo C . Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol. 2006; 24(5):778-89. DOI: 10.1200/JCO.2005.03.2375. View

van Wilpe S, Gerretsen E, van der Heijden A, de Vries I, Gerritsen W, Mehra N . Prognostic and Predictive Value of Tumor-Infiltrating Immune Cells in Urothelial Cancer of the Bladder. Cancers (Basel). 2020; 12(9). PMC: 7565173. DOI: 10.3390/cancers12092692. View

McFaline-Figueroa J, Hill A, Qiu X, Jackson D, Shendure J, Trapnell C . A pooled single-cell genetic screen identifies regulatory checkpoints in the continuum of the epithelial-to-mesenchymal transition. Nat Genet. 2019; 51(9):1389-1398. PMC: 6756480. DOI: 10.1038/s41588-019-0489-5. View

Yang W, Soares J, Greninger P, Edelman E, Lightfoot H, Forbes S . Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2012; 41(Database issue):D955-61. PMC: 3531057. DOI: 10.1093/nar/gks1111. View

10.

Takeuchi H, Tanaka M, Tanaka A, Tsunemi A, Yamamoto H . Predominance of M2-polarized macrophages in bladder cancer affects angiogenesis, tumor grade and invasiveness. Oncol Lett. 2016; 11(5):3403-3408. PMC: 4841030. DOI: 10.3892/ol.2016.4392. View

11.

Liu J, Zheng Z, Zhang W, Wan M, Ma W, Wang R . Dysregulation of tumor microenvironment promotes malignant progression and predicts risk of metastasis in bladder cancer. Ann Transl Med. 2021; 9(18):1438. PMC: 8506754. DOI: 10.21037/atm-21-4023. View

12.

Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M . Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2020; 21(6):341-352. PMC: 7250738. DOI: 10.1038/s41580-020-0237-9. View

13.

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

14.

Wang M, Zhang Z, Pan D, Xin Z, Bu F, Zhang Y . Circulating lncRNA UCA1 and lncRNA PGM5-AS1 act as potential diagnostic biomarkers for early-stage colorectal cancer. Biosci Rep. 2021; 41(7). PMC: 8276091. DOI: 10.1042/BSR20211115. View

15.

Powles T, Duran I, van der Heijden M, Loriot Y, Vogelzang N, De Giorgi U . Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2017; 391(10122):748-757. DOI: 10.1016/S0140-6736(17)33297-X. View

16.

Jain R, Shaul P, Borok Z, Willis B . Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-beta1. Am J Respir Cell Mol Biol. 2007; 37(1):38-47. PMC: 1899351. DOI: 10.1165/rcmb.2006-0353OC. View

17.

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

18.

Li X, Huang C, Liu Z, Jiang L, Chen J, Xie D . Prognostic Role of the Immunoscore for Patients with Urothelial Carcinoma of the Bladder Who Underwent Radical Cystectomy. Ann Surg Oncol. 2019; 26(12):4148-4156. DOI: 10.1245/s10434-019-07529-y. View

19.

Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov J . Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011; 27(12):1739-40. PMC: 3106198. DOI: 10.1093/bioinformatics/btr260. View

20.

Koelwyn G, Quail D, Zhang X, White R, Jones L . Exercise-dependent regulation of the tumour microenvironment. Nat Rev Cancer. 2017; 17(10):620-632. DOI: 10.1038/nrc.2017.78. View